2021 News Releases
Puma Biotechnology to Present at the J.P. Morgan Healthcare Conference
LOS ANGELES, Calif., Jan. 5, 2021 - Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical
company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of
Puma, will provide an overview of the Company at the 39 th Annual J.P. Morgan Healthcare
Conference, which will be held virtually. Puma’s presentaion will take place at 7:50 a.m. PST
(10:50 a.m. EST) on Thursday, January 14, 2021.
A live webcast of the presentation will be available on the Company’s website at
www.pumabiotechnology.com. The presentation will be archived on the website and available for 30 days.
About Puma Biotechnology
Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and
commercialization of innovative products to enhance cancer care. Puma in-licenses the global development
and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357.
Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant
treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant
trastuzumab-based therapy, and is marketed in the United States as NERLYNX® (neratinib) tablets. In
February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the
treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two
or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing
authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with
early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than
one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX is a registered trademark
of Puma Biotechnology, Inc.
Alan H. Auerbach or Mariann Ohanesian, Puma Biotechnology, Inc., +1 424 248 6500
David Schull or Maggie Beller, Russo Partners, +1 212 845 4200
# # # # #
Back to 2021 News Releases
Puma Biotechnology, Inc.
10880 Wilshire Blvd., Suite 2150
Los Angeles, CA 90024